Skip to content
value.today

Moderna, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $4.3 B to $19.2 B, median $9.6 BPrice to bookPrice to book of Biotechnology: $26.5 B to $111.5 B, median $38.8 B$0 M$30.1 B$60.2 B$90.3 B$120.4 BMarket value $90.1 B

Your own DCF model

A full discounted-cash-flow model of Moderna, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Moderna, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Moderna, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 9.9×35.7×revenue $1.9 B$4.3 B to $19.2 B84
Price to book3.1× / 4.5× / 12.9×10.4×book equity $8.7 B$26.5 B to $111.5 B69

Against its own history

Moderna, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

40.5×

Now above its median of 4.2×, in the top quarter of its range; range 2.1× to 689.0× over 30 months.

0×172×345×517×689×2020202120222023202420252026Price to sales 40×Median 4×

Price to book

10.4×

Now above its median of 1.8×, in the top quarter of its range; range 0.8× to 35.2× over 30 months.

0×9×18×26×35×2020202120222023202420252026Price to book 10×Median 2×

As of Oct 30, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$1.9 B$-2.8 B$-1.9 B$192 M$-2.1 B$-2.0 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$3.2 B$-3.6 B$-3.0 B$1.1 B$-4.1 B$-1.9 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$6.8 B$-4.7 B$-3.1 B$707 M$-3.8 B—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$19.3 B$8.4 B$5.0 B$400 M$4.6 B—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$18.5 B$12.2 B$13.6 B$284 M$13.3 B—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$803 M$-747 M$2.0 B$68 M$2.0 B—SEC annual report (10-K, 20-F)